Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | GMNN | O75496 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9632302 | 1.00 | CES2 (0.50) | CES2MAPK1GMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL7561213 | 1.00 | CES2 (0.50) | CES2MAPK1GMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL5316578 | 0.98 | CES2 (0.48) | CES2MAPK1GMNNLMNAMAPT | |
| Water SCHEMBL16968728 | 0.98 | CES2 (0.48) | CES2MAPK1GMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL5316381 | 0.98 | CES2 (0.48) | CES2MAPK1GMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL5317631 | 0.98 | CES2 (0.48) | CES2MAPK1GMNNLMNAMAPT | |
| SCHEMBL5317333 | 0.98 | CES2 (0.52) | CES2MAPK1GMNNLMNAMAPT | |
| SCHEMBL198090 | 0.98 | CES2 (0.52) | CES2MAPK1GMNNLMNAMAPT | |
| SCHEMBL5319042 | 0.98 | CES2 (0.52) | CES2MAPK1GMNNLMNAMAPT | |
| SCHEMBL200766 | 0.98 | CES2 (0.52) | CES2MAPK1GMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113358528-B | Method for detecting acetylcholinesterase and inhibitor thereof based on pendant drop method | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| CN-113358528-A | Method for detecting acetylcholinesterase and inhibitor thereof based on pendant drop method | 山东大学 | 2021-09-07 | — | — | CN | claimed |
| EP-3105348-A1 | METHODS OF NUCLEIC ACID CAPTURE | Zymo Research Corporation (US) | 2016-12-21 | — | — | EP | claimed |
| WO-2015120447-A1 | METHODS OF NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2015-08-13 | — | — | WO | claimed |
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4148141-B1 | KIT FOR NUCLEIC ACID CAPTURE | ZYMO RES CORPORATION (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20250270537-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2024246607-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2024-12-05 | — | — | WO | disclosed |
| EP-4148141-A1 | KITS FOR NUCLEIC ACID CAPTURE | Zymo Research Corporation (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3653723-B1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RES CORPORATION (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-113358528-B | Method for detecting acetylcholinesterase and inhibitor thereof based on pendant drop method | 山东大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-113358528-A | Method for detecting acetylcholinesterase and inhibitor thereof based on pendant drop method | 山东大学 | 2021-09-07 | — | — | CN | disclosed |
| EP-3653723-A1 | METHODS FOR NUCLEIC ACID CAPTURE | Zymo Research Corporation (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3105348-B1 | METHODS OF NUCLEIC ACID CAPTURE | ZYMO RES CORPORATION (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20180371450-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RES CORPORATION (US) | 2018-12-27 | — | — | US | disclosed |
| EP-3105348-A1 | METHODS OF NUCLEIC ACID CAPTURE | Zymo Research Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| CN-105241882-A | Applications of liquid crystal sensor in detection of organophosphorus pesticides and carbamate pesticides | UNIV SHANDONG | 2016-01-13 | — | — | CN | disclosed |
| US-20150225713-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION | 2015-08-13 | — | — | US | disclosed |
| WO-2015120447-A1 | METHODS OF NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SLC10A2, SLC5A7, SLC18A3 | CES2 156/4885MAPK1 3672/4885GMNN 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.